Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance
Authors not listed
The University of Texas Health Science Center at San Antonio · 2023
Abstract
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-03 MST
Cite this
APA
Anonymous. (2023). The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance. <em>The University of Texas Health Science Center at San Antonio</em>. https://clinicaltrials.gov/study/NCT05786521
Vancouver
Anonymous. The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance. The University of Texas Health Science Center at San Antonio. 2023.
BibTeX
@misc{anon2023TheEff,
title = {The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance},
author = {Anonymous},
journal = {The University of Texas Health Science Center at San Antonio},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Mayo Clinic 2025
Open access · US-GOV
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Second Affiliated Hospital, Zhejiang University, School of Medicine 2025
Open access · US-GOV
Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology
Nutrients 2018
Open access · CC-BY
Dietary Protein and Muscle in Aging People: The Potential Role of the Gut Microbiome
Versanis Bio, Inc. 2021
Open access · US-GOV
An Observational Study to Assess the Feasibility and Variability of Physical Assessments Performed by People 45 Years of Age or Older Who Are Overweight or Obese
Weinkle, Susan H., M.D. 2009
Open access · US-GOV
Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®
Tel-Aviv Sourasky Medical Center 2025
Open access · US-GOV